{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:26:19Z","timestamp":1788582379756,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006704","name":"Ostravsk\u00e1 Univerzita v Ostrav\u011b","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministry of Education Youth and Sports of the Czech Republic","doi-asserted-by":"publisher","award":["SGS12\/LF\/2021"],"award-info":[{"award-number":["SGS12\/LF\/2021"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.msard.2024.106246","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T07:42:32Z","timestamp":1734766952000},"page":"106246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Whole blood concentrations of fingolimod and its pharmacologically active metabolite fingolimod phosphate obtained during routine health care of patients with multiple sclerosis"],"prefix":"10.1016","volume":"93","author":[{"given":"Ivana","family":"Kacirova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1502-9741","authenticated-orcid":false,"given":"Zuzana Krska","family":"Kusnirikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Pesakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Hradilek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Brozmanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Grundmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.106246_bib0014","first-page":"1","volume":"44","author":"Agency","year":"2012","journal-title":"Guideline on bioanalytical method validation"},{"issue":"3","key":"10.1016\/j.msard.2024.106246_bib0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40268-020-00316-1","article-title":"Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis","volume":"20","author":"Bascu\u00f1ana","year":"2020","journal-title":"Drugs R D"},{"issue":"6","key":"10.1016\/j.msard.2024.106246_bib0015","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.msard.2024.106246_bib0007","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/11596550-000000000-00000","article-title":"Clinical pharmacokinetics of fingolimod","volume":"51","author":"David","year":"2012","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.msard.2024.106246_bib0003","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis - a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.msard.2024.106246_bib0001","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.mcna.2018.10.004","article-title":"Multiple Sclerosis and Autoimmune Neurology of the Central Nervous System","volume":"103","author":"Galetta","year":"2019","journal-title":"Med Clin North Am"},{"issue":"12","key":"10.1016\/j.msard.2024.106246_bib0002","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of Multiple Sclerosis: A Review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am J Med"},{"key":"10.1016\/j.msard.2024.106246_bib0009","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pharmthera.2017.11.001","article-title":"The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives","volume":"185","author":"Huwiler","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.msard.2024.106246_bib0011","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/cpdd.813","article-title":"Bioequivalence Study of 2 Capsule Formulations of Fingolimod 0.5 mg Assessing Both Parent Drug and Active Metabolite in New Zealand Healthy Subjects (Truncated Design)","volume":"9","author":"Hung","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"10.1016\/j.msard.2024.106246_bib0008","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1586\/14737175.2016.1123094","article-title":"Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis","volume":"16","author":"Jeffery","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.msard.2024.106246_bib0005","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaut.2014.01.022","article-title":"The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review","volume":"48-49","author":"Karussis","year":"2014","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.msard.2024.106246_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.msard.2024.106246_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.122910","article-title":"Serum teriflunomide concentrations in routine multiple sclerosis therapy: A cross-sectional pilot study","volume":"458","author":"Kusnirikova","year":"2024","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.msard.2024.106246_bib0017","doi-asserted-by":"crossref","DOI":"10.2174\/0118715273302279240529104919","article-title":"Analysis of Concentrations of Monomethyl Fumarate in Patients with Multiple Sclerosis: Result from Routine Health Care","author":"Kusnirikova","year":"2024","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"2","key":"10.1016\/j.msard.2024.106246_bib0012","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/eye.2016.258","article-title":"Fingolimod: therapeutic mechanisms and ocular adverse effects","volume":"31","author":"Mandal","year":"2017","journal-title":"Eye (Lond)"},{"issue":"6","key":"10.1016\/j.msard.2024.106246_bib0004","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/WCO.0000000000000622","article-title":"Multiple sclerosis: clinical aspects","volume":"31","author":"Oh","year":"2018","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.msard.2024.106246_bib0013","doi-asserted-by":"crossref","first-page":"e5947","DOI":"10.1002\/bmc.5947","article-title":"Liquid chromatography\u2013tandem mass spectrometry for determination of fingolimod and its active metabolite fingolimod phosphate in whole blood of patients with multiple sclerosis","author":"Pesakova","year":"2024","journal-title":"Biomedical Chromatography"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824008228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824008228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T21:00:03Z","timestamp":1738184403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824008228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":17,"alternative-id":["S2211034824008228"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.106246","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Whole blood concentrations of fingolimod and its pharmacologically active metabolite fingolimod phosphate obtained during routine health care of patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.106246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106246"}}